ALK and non-small cell lung carcinoma: Despite improvements in overall survival for patients with ALK‐positive NSCLC who are treated with crizotinib, patients diagnosed with NSCLC, in general, have an average life expectancy of ranging from 10 to 26.7 months,10 and this may have contributed to the relatively low response rate.